Logo image of ARTV

ARTIVA BIOTHERAPEUTICS INC (ARTV) Stock Fundamental Analysis

NASDAQ:ARTV - US04317A1079 - Common Stock

3.15 USD
0 (0%)
Last: 9/2/2025, 10:47:19 AM
Fundamental Rating

3

ARTV gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 542 industry peers in the Biotechnology industry. ARTV has a great financial health rating, but its profitability evaluates not so good. ARTV does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ARTV has reported negative net income.
In the past year ARTV has reported a negative cash flow from operations.
ARTV Yearly Net Income VS EBIT VS OCF VS FCFARTV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -44.08%, ARTV perfoms like the industry average, outperforming 55.54% of the companies in the same industry.
With a decent Return On Equity value of -50.09%, ARTV is doing good in the industry, outperforming 65.68% of the companies in the same industry.
Industry RankSector Rank
ROA -44.08%
ROE -50.09%
ROIC N/A
ROA(3y)-34.23%
ROA(5y)N/A
ROE(3y)-55.15%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ARTV Yearly ROA, ROE, ROICARTV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

ARTV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARTV Yearly Profit, Operating, Gross MarginsARTV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

7

2. Health

2.1 Basic Checks

ARTV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ARTV has been increased compared to 1 year ago.
Compared to 1 year ago, ARTV has a worse debt to assets ratio.
ARTV Yearly Shares OutstandingARTV Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M
ARTV Yearly Total Debt VS Total AssetsARTV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

ARTV has an Altman-Z score of -0.72. This is a bad value and indicates that ARTV is not financially healthy and even has some risk of bankruptcy.
ARTV has a Altman-Z score (-0.72) which is in line with its industry peers.
There is no outstanding debt for ARTV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.72
ROIC/WACCN/A
WACC9.86%
ARTV Yearly LT Debt VS Equity VS FCFARTV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

ARTV has a Current Ratio of 13.84. This indicates that ARTV is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 13.84, ARTV belongs to the top of the industry, outperforming 88.19% of the companies in the same industry.
ARTV has a Quick Ratio of 13.84. This indicates that ARTV is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ARTV (13.84) is better than 88.19% of its industry peers.
Industry RankSector Rank
Current Ratio 13.84
Quick Ratio 13.84
ARTV Yearly Current Assets VS Current LiabilitesARTV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for ARTV have decreased strongly by -370.69% in the last year.
ARTV shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -99.25%.
Measured over the past years, ARTV shows a very negative growth in Revenue. The Revenue has been decreasing by -49.95% on average per year.
EPS 1Y (TTM)-370.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.05%
Revenue 1Y (TTM)-99.25%
Revenue growth 3Y-49.95%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ARTV will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.82% on average per year.
ARTV is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -25.99% yearly.
EPS Next Y34.8%
EPS Next 2Y16.57%
EPS Next 3Y14.83%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ARTV Yearly Revenue VS EstimatesARTV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 10M 20M 30M
ARTV Yearly EPS VS EstimatesARTV Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ARTV. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARTV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARTV Price Earnings VS Forward Price EarningsARTV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARTV Per share dataARTV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as ARTV's earnings are expected to grow with 14.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.57%
EPS Next 3Y14.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ARTV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARTIVA BIOTHERAPEUTICS INC

NASDAQ:ARTV (9/2/2025, 10:47:19 AM)

3.15

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)N/A N/A
Inst Owners81.33%
Inst Owner Change-11.87%
Ins Owners0.91%
Ins Owner Change2.43%
Market Cap76.95M
Analysts85
Price Target15.71 (398.73%)
Short Float %1.65%
Short Ratio1.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-10.13%
Min EPS beat(2)-14.53%
Max EPS beat(2)-5.74%
EPS beat(4)2
Avg EPS beat(4)5.8%
Min EPS beat(4)-14.53%
Max EPS beat(4)29.15%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-24.51%
EPS NQ rev (1m)-3.78%
EPS NQ rev (3m)-8.21%
EPS NY rev (1m)-5.4%
EPS NY rev (3m)-6.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.52
P/tB 0.52
EV/EBITDA N/A
EPS(TTM)-3.02
EYN/A
EPS(NY)-3.47
Fwd EYN/A
FCF(TTM)-2.89
FCFYN/A
OCF(TTM)-2.82
OCFYN/A
SpS0
BVpS6.1
TBVpS6.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.08%
ROE -50.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.23%
ROA(5y)N/A
ROE(3y)-55.15%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 68.84%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.84
Quick Ratio 13.84
Altman-Z -0.72
F-Score3
WACC9.86%
ROIC/WACCN/A
Cap/Depr(3y)238.05%
Cap/Depr(5y)N/A
Cap/Sales(3y)131.08%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-370.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.05%
EPS Next Y34.8%
EPS Next 2Y16.57%
EPS Next 3Y14.83%
EPS Next 5YN/A
Revenue 1Y (TTM)-99.25%
Revenue growth 3Y-49.95%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y-119.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.03%
OCF growth 3YN/A
OCF growth 5YN/A